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Purpose: To evaluate cyclooxygenase-2 (COX-2) expression and to characterize COX-2-expressing stromal cells in
human pterygium.
Methods: Primary pterygium tissue of Korean patients (eight males and nine females) was analyzed. The clinical
characteristics were classified, and immunohistochemical staining using primary antibodies against cyclooxygenease-2,
vascular endothelial growth factor-A, cluster of differentiation (CD)68, CD3, CD20, and leukocyte common antigen was
performed.
Results: COX-2 expression was detected in all pterygium tissues evaluated (17 primary pterygia). Diffuse expression of
COX-2 in the epithelial layer was observed in nine samples. Infiltration of strongly positive COX-2 cells into the epithelial
layer was a more common observation than diffuse epithelial COX-2 expression. Scattered COX-2-expressing cells in
the stromal layer were found in all samples. Some COX-2-positive cells were found within microvessels. In addition to
stromal COX-2-expressing cells, a few vascular endothelial cells strongly expressed COX-2; however most of the vessels
were negative for COX-2 expression. Stromal COX-2-expressing cells were positive for the macrophage marker CD68
and co-expressed vascular endothelial growth factor. COX-2 expression in normal conjunctiva was not observed in seven
control samples.
Conclusions: These COX-2- and vascular endothelial growth factor-expressing macrophages may have relevance to the
pathogenesis of pterygium.
Human pterygium is made up of chronic proliferative
fibro-vascular  tissue  growing  on  the  ocular  surface.  This
disease exhibits both degenerative and hyperplastic properties
[1,2].  Ultraviolet  (UV)-light  damage,  dry  and  dusty
environments,  and  repeated  microtrauma  can  lead  to
development of pterygium in susceptible individuals [1,3,4].
Immunological mechanisms both humoral (Immunoglobulin
[Ig] A, IgM, and IgG) and cellular (lymphocytes, plasma cells,
and  mast  cells)  are  believed  to  play  roles  in  pterygium
development and recurrence [5-8]. Tumor-like characteristics
of pterygium, such as virus infection by the likes of human
papilloma virus, inactivation of tumor suppressor gene p53,
and co-existence with ocular surface neoplasm, have been
reported [9-11]. Possible roles of bone marrow progenitor
cells and neuronal signals in pterygium have recently been
suggested  [12-14].  Hyper-vascularity  is  one  of  the
characteristic  cosmetic  problems  of  pterygium  and  leads
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young patients to surgical removal of the lesion. Although the
exact  pathogenesis  is  still  unclear,  chronic  inflammation,
angiogenesis,  and  uncontrolled  proliferation  are  the  key
features  of  pterygium  [1,2,4,15].  Therefore,  it  is  highly
suspected that several inflammatory and angiogenic factors
are closely related to its pathogenesis.
Cyclooxygenase-2 (COX-2) is an inducible isoform of
cyclooxygenases and is the key enzyme for inflammatory
cytokine-induced  angiogenesis.  Recently,  COX-2  was
reported  to  increase  vascular  endothelial  growth  factor
(VEGF)  expression  in  chronic  inflammation  and  various
tumors  [16-20].  While  cyclooxygenase-1  is  constitutively
expressed in most types of cells and tissues, COX-2 is rapidly
induced by growth factors, cytokines, bacterial endotoxins,
and  tissue  damage.  COX-2  is  also  involved  in  the
pathogenesis  of  skin  tumors  in  conjunction  with  reactive
oxygen  species  generated  by  UV  damage.  Recent  studies
indicate COX-2 expression in human pterygium and suggest
its role in disease pathogenesis and prognosis after surgical
excision [21-24].
Although several previous studies verified the existence
of COX-2 expression in human pterygium, there has been no
study  to  characterize  these  COX-2-expressing  cells  and
investigate the correlation with VEGF. Therefore, the aim of
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3468this  study  is  to  investigate  the  characteristics  of  COX-2-
expressing cells in pterygium. In addition to analyzing the
spatial  distribution  of  COX-2-expressing  cells,  various
inflammatory cell markers were used to characterize them.
Finally,  the  co-expression  of  COX-2  and  VEGF  was
evaluated.
METHODS
Primary  pterygium  tissue  was  harvested  after  obtaining
informed consent from Korean patients (eight males and nine
females). All patients were diagnosed with primary pterygium
in  the  nasal  conjunctiva.  None  had  been  under  topical
medication treatment except for artificial tear drops. No sign
of severe inflammation of pterygium was observed in any of
the  patients.  Normal  conjunctiva  was  harvested  from  the
superior conjunctiva of seven patients (four males and three
females, ages from 59 to 78 years) after obtaining informed
consent when they underwent cataract surgery.
Clinical  classification  of  pterygium:  The  clinical
characteristics of pterygium were classified using a modified
classification system [25]. The stage of pterygium was rated
as stage I, tissue involvement of limbus; stage II, tissue just
on  the  limbus;  stage  III,  tissue  between  the  limbus  and
pupillary margin; and stage IV, tissue central to the pupillary
margin. The surface vascularity (V) of pterygium was scored
as score +, minimal visible vessel (equal to conjunctiva); score
++, moderate vascularity (more dense than conjunctiva); and
score  +++,  severe  vascularity  with  vessel  congestion.
Conjunctival tissue thickenss (C) was classified as C1, flat
tissue; C2, minimally elevated tissue; C3, tissue elevation up
to 1 mm; and C4, tissue elevation over 1 mm. Corneal tissue
thickness (K) was classified as K1, flat tissue; K2, minimally
TABLE 1. DESCRIPTION OF PRIMARY ANTIBODIES USED IN THE STUDY.
Target Description Manufacturer Catalog no.
Cyclooxygenease-2 Rabbit polyclonal Abcam ab15191
Vascular endothelial growth factor-A Mouse monoclonal Abcam ab1316
CD68 Mouse monoclonal Dako M0876
CD38 Mouse monoclonal Dako F7101
CD3 Rabbit polyclonal Dako A 0452
CD20 Mouse monoclonal Dako IR604
Leukocyte common antigen Mouse monoclonal Dako M 0701
Alexa Fluor 594   invitrogen A11012
Alexa Fluor 488   invitrogen A11001
TABLE 2. CLINICAL CHARACTERISTICS AND CYCLOOXYGENASE-2 EXPRESSION PATTERN OF PTERYGIA STUDIED WERE DEMONSTRATED.
Case No. Sex/Age Stage V C K COX-2 (epithelial layer) COX-2 (stromal vessels) COX-2 (stromal layer)
1 M/52 III +++ C3 K2 ++ - +++
2 F/53 III ++ C2 K2 0 - +++
3 F/50 II ++ C3 K1 ++ + +
4 M/43 III +++ C2 K2 + - ++
5 M/57 II ++ C3 K2 0 - ++
6 M/39 III +++ C3 K1 ++ + +++
7 F/53 II ++ C3 K2 0 - ++
8 F/33 III +++ C2 K2 0 - ++
9 M/74 III ++ C2 K2 0 - ++
10 M/66 III +++ C2 K2 +++ + +++
11 F/47 III ++ C3 K2 + - +
12 M/59 III ++ C2 K2 0 - ++
13 F/52 II ++ C2 K1 0 - +
14 M/60 III ++ C2 K2 + - ++
15 F/47 II ++ C2 K1 0 - +
16 F/53 III +++ C3 K2 +++ + +++
17 F/55 II ++ C2 K2 + - ++
        Stage: I, tissue involvement of limbus; II, tissue just on the limbus; III, tissue between the limbus and pupillary margin; and IV,
        tissue central to the pupillary margin. Surface vascularity (V): +, minimal visible vessel (equal to conjunctiva); ++, moderate
        vascularity (more dense than conjunctiva); and +++, severe vascularity with vessel congestion. Conjunctival tissue thickenss
        (C): C1, flat tissue; C2, minimally elevated tissue; C3, tissue elevation up to 1mm; and C4, tissue elevation over 1mm. Corneal
        tissue thickness (K): K1, flat tissue; K2, minimally elevated tissue; K3, tissue elevation up to 1mm; and K4, tissue elevation
        over 1mm. COX-2 expression in the epithelial layer: score 0, negative staining; score +, from 1 to 10%; score ++, from 11 to
        50%; and score +++, more than 50% positive cells. COX-2 expression in the stromal layer: score 0, no positive cells; score +,
        from 1 to 5 positive cells; score ++, from 6 to 10 positive cells; and score +++, more than 10 positive cells.
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3469Figure 1. Cyclooxygenase-2 expression in pterygium tissue. A: Hematoxylin and eosin staining of human pterygium (case 10) is demonstrated.
B: Immunohistochemistry of human pterygium using anti-cyclooxygenase-2(COX-2) antibody was performed. Diffuse expression (grade 2)
of COX-2 is seen in the epithelial layer with some strong COX-2-expressing cells in both the epithelium and stroma. Endothelial cells lining
vessels were also strongly positive for COX-2 expression in this sample. The arrow indicates the magnified area. C, D: COX-2 expression
was not found in the epithelial or stromal layer in the normal control. E: Strong COX-2 expression in colon cancer was demonstrated as the
positive control. F: western blot analysis revealed various degrees of COX-2 expression in pterygium tissue (cases 2, 3, 4, 6, and 10); however,
no COX-2 band was observed in the control tissue.
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3470elevated tissue; K3, tissue elevation up to 1 mm; and K4, tissue
elevation over 1 mm. This study was performed with approval
from the Institutional Review Board of Dongguk University
Hospital, Koyang, South Korea.
Immunohistochemical study: For immunohistochemical
studies,  4-µ-thick  sections  were  obtained  from  formalin-
fixed, paraffin-embedded tissues and were transferred onto
adhesive  slides  and  dried  at  60  °C  for  40  min.
Immunohistochemical  procedures  were  performed  using  a
BenchMark  XT  automatic  immunohistochemical  staining
device (Ventana Medical System, Tucson, AZ). In brief, after
dewaxing and rehydrating, antigen retrieval was performed
using microwave technique (citrate buffer, pH 6.0, twenty-
five min in a microwave oven). The slides were then incubated
for 30 min at 42 °C with primary antibodies. The primary
antibody  was  detected  using  iVIEW  DAB  detection  kit
(Ventana  Medical  System),  which  is  highly  specific  and
sensitive to rabbit and mouse immunoglobulins. The detailed
information of the primary antibodies used in this study is
provided in Table 1.
COX-2 expression in the epithelial layer was scored for
the percentage of positive-staining cells: 0, negative staining;
+, from 1 to 10%; ++, from 11 to 50%; and +++, more than
50% positive cells. COX-2 expression in the stromal layer was
scored for the average number of COX-2-expressing cells
calculated over ten random high-power fields (400×): 0, no
positive cells; +, from one to five positive cells; ++, from six
to ten positive cells; and +++, more than ten positive cells.
Western blot analysis: For western blot analysis, the parts
of pterygium tissues (case 2, 3, 4, 6, 10, and 16) stored at –
80 °C were quickly homogenized with a tissue crusher while
frozen, and the tissue powder was placed into boiling lysis
buffer (1% SDS, 1.0 mM sodium ortho-vanadate, 10 mM Tris
[pH  7.4]),  placed  into  a  microwave  oven  for  15  s,  and
centrifuged for 5 min at 11,400× g at 15 °C. The samples were
then separated via SDS–PAGE under denaturing conditions
and electroblotted onto a polyvinylidine difluoride membrane
(BioRad, Hercules, CA). After being blocked using 5% nonfat
dry milk in Tris-buffered saline containing 10 mM Tris (pH
7.6), 150 mM NaCl, and 0.1% Tween-20, the membranes
were  incubated  with  anti-COX-2  antibodies  (catalog  no:
ab15191; Abcam, Cambridge, MA), and diluted to 1:200 in
blocking solution overnight at 4 °C. The membranes were
further incubated with an antirabbit horseradish peroxidase-
conjugated antibody (Santa Cruz Biotechnology, Santa Cruz,
CA).  They  were  then  treated  with  an  enhanced
chemiluminescence solution (Pierce Fast Western Blot kit;
Thermo fisher Scientific, Rockford, IL), and the signals were
captured on an image reader (Las-3000; Fuji Photo Film,
Tokyo, Japan). To monitor the amount of protein loaded into
Figure 2. Anterior segment photographs of representative pterygium cases. Upper panels (A-C) demonstrate cases 6, 10, and 16. The surface
vascularity of these pterygia was scored as +++. These cases revealed strong cyclooxygenase (COX-2) expression both in the epithelial and
stromal layers. Lower panels (D-F) demonstrate cases 11, 13, and 15. These pterygia look slightly atrophic, and the vascularity was scored
as ++. Relatively fewer COX-2-expressing stromal cells were found in these cases compared to cases of the upper panel. The surface vascularity
of pterygium was scored as score +, minimal visible vessel (equal to conjunctiva); score ++, moderate vascularity (more dense than
conjunctiva); and score +++, severe vascularity with vessel congestion.
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3471Figure 3. The various patterns of cyclooxygenase-2 expression in human pterygium. Panels A to C demonstrate score 0 (A, case 13), score +
+ (B, case 1) and score +++ (C, case 16) expression of cyclooxygenase-2 (COX-2) in the epithelial layer of pterygium. Strong COX-2-
expressing stromal cells were always observed. D: A few COX-2-expressing cells were found within a cluster of inflammatory cells in case
4. E: These inflammatory cells were mostly CD3-expressing T cells. F: The epithelial layer of panel C shows a few, scattered, strong COX-2-
expressing cells. G: COX-2-expressing cells in panel B were magnified. These cells were found near blood vessels; however, endothelial cells
were negative for COX-2 expression. Three cells show very strong positive COX-2 expression both in the cytoplasm and in the nucleus. H:
Strong COX-2-expressing cells were localized within microvessels (case 15). The arrow indicates the magnified area. I: Inflammatory cells
within vessels show segmented nuclei; however, these cells were negative for COX-2 expression (inserted image). A few endothelial cells
express COX-2 (case 6). COX-2 expression in the epithelial layer was scored for the percentage of positive-staining cells: 0, negative staining;
+, from 1 to 10%; ++, from 11 to 50%; and +++, more than 50% positive cells.
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3472each lane, the membranes were treated with a stripping buffer
and re-probed with a monoclonal antibody against β-actin
(Sigma-Aldrich,  St  Louis,  MO).  The  protein  bands  were
analyzed via densitometry. The ratio between COX-2 and β-
actin was calculated.
Statistical analysis: The χ2 test was used for statistical
analysis.  P  values  less  than  0.05  were  considered  to  be
significant.
RESULTS
The clinical characteristics of the pterygium studied are listed
in Table 2. COX-2 expression in the primary pterygium was
verified by immunohistochemistry and western blot analysis.
Diffuse  expression  of  COX-2  in  the  epithelial  layer  was
observed in nine samples (Table 2; Figure 1). Infiltration of
strong COX-2-expressing cells into the epithelial layer was
observed  in  samples  showing  diffuse  epithelial  COX-2
expression. Stromal COX-2 expression was more prominent
in pterygia having prominent vascularity compared to pteygia
having  atrophic  appearance  (Figure  2).  Scattered  COX-2-
expressing cells in the stromal layer were more common and
were  found  in  all  samples  (Figure  3).  These  COX-2-
expressing stromal cells were readily detectable around blood
vessels  and  were  scattered  rather  than  clustered.  Some
strongly  expressing  COX-2  cells  were  located  within
microvessels, suggesting that these cells were migrating from
blood vessels (Figure 3H). Some vascular endothelial cells
strongly expressed COX-2, as found in four samples (Figure
1B). However, most of the stromal vessel endothelial cells
showed negative expression of COX-2 (13 samples; Figure
3G).  Interestingly,  four  samples  expressing  endothelial
COX-2  expressed  higher  grade  (++  or  +++)  of  epithelial
COX-2 compared to other samples (p=0.002, χ2 test). Higher
grade (+++) of stromal COX-2 expression was also more
frequently found in these four samples (p=0.010, χ2 test). In
addition, three samples of these (75%) were classified as stage
III and V +++. Considering only 35% of studied samples
showed both stage III and V +++, it is possible that vascular
COX-2 expression is related to clinical severity, although
statistical  significance  was  not  reached  due  to  the  small
sample  size  (p=0.099,  χ2  test).  White  blood  cells  with
segmented nuclei were occasionally found in the stromal area
Figure 4. Lymphocytes and macrophages scattered throughout the pterygium. Immunohistochemistry using anti-leukocyte common antigen
(LCA), anti-CD3, and anti-CD68 antibodies showed the characteristic distribution of inflammatory cells. A-C: Tissue image was obtained
from case 4. D-F: Tissue image was obtained from case 8. LCA and CD3 staining showed a similar clustered distribution, suggesting most
LCA-expressing cells are T cells. CD68-expressing cells are smaller in population and have an evenly scattered distribution.
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3473but were negative for COX-2 expression (Figure 3I). T cells
and macrophages were scattered throughout the pterygium. T
cells were the largest population of inflammatory cells and
showed  a  clustered  pattern  in  distribution,  whereas
macrophages were small in population but showed evenly
scattered  distribution  (Figure  4).  Most  of  the  COX-2-
expressing stromal cells had round- to oval-shaped cytoplasm,
and both nucleus and cytoplasm were strongly stained (Figure
5).  The  distribution  pattern  and  the  shapes  of  COX-2-
expressing stromal cells raised the suspicion that these cells
were infiltrating inflammatory cells. Subsequent staining with
inflammatory cell markers (CD3, CD20, CD68, CD38, and
leukocyte  common  antigen)  revealed  that  the  cells  were
CD68-expressing macrophages (Figure 5, Figure 6, Figure 7).
Stromal  COX-2-expressing  cells  co-expressed  VEGF;
however, VEGF-expressing vascular endothelial cells were
Figure 5. Expression of cyclooxygenase-2 (COX-2), leukocyte common antigen (LCA), and CD3. A: COX-2-expressing cells have round
and oval shapes. B: A magnified view of the outlined area of panel A. COX-2-expressing cells have oval shapes and abundant cytoplasm.
Strong COX-2 staining was observed both in the cytoplasm and in the nucleus. (arrowheads) C-D: Immunohistochemistry of adjacent sections
of tissue with anti-LCA and anti-CD3 antibodies (T-cell marker) was performed. COX-2-expressing cells (arrows 1 to 5) showed different
distributions compared to inflammatory cells expressing LCA or CD3 (case 7).
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3474mostly negative for COX-2 expression (Figure 8). COX-2
expression in normal conjunctiva was not observed in seven
control samples (Figure 1, Figure 9).
DISCUSSION
Several  theories  have  been  suggested  concerning  the
pathogenesis  of  human  pterygium.  The  observed  heavy
infiltration of inflammatory cells and immunoglobulins has
been  suggested  as  evidence  for  an  immune  process  in
pterygium pathogenesis [1,2,4]. On the other hand, COX-2
expression  and  attenuation  of  p53  along  with  UV-light
damage has suggested tumor-like characteristics of pterygium
[1,2,4,26]. Degenerative change and stem cell involvement
have also been verified in previous studies [1,4,12].
COX-2  expression  in  human  pterygium  has  been
previously studied. Chiang et al. found that more than 80% of
pterygium  tissue  studied  showed  positive  expression  of
COX-2 in the epithelial layer; however, they found no COX-2
expression in the stromal layer [22]. Subsequent studies by
Karahan et al. [23] and Maxia et al. [24] reported COX-2
expression in the epithelial layer of primary pterygia, at 84.2%
and  67.7%,  respectively.  They  also  reported  COX-2
expression in the stromal layers. Capillaries, inflammatory
cells, and stromal cells were positive for COX-2 expression
in these studies. Strong COX-2 expression was suggested as
a risk factor for recurrence of pterygium [21,23]. In our study,
nine  out  of  17  pterygia  (52.9%)  expressed  COX-2  in  the
epithelial layer and 100% expressed COX-2 in the stromal
layer, especially in macrophages infiltrating the lesion. The
heterogeneity of epithelial COX-2 expression may be related
to the inflammatory state of the ocular surface; however, the
Figure 6. Expression of cyclooxygenase-2 (COX-2), CD38, and CD20. A-C: Immunohistochemistry of adjacent sections of tissue with anti-
CD38, anti-COX-2, and anti-CD20 antibodies (B cell marker) was performed in case 11. CD38-expressing plasma cells were scattered through
the stromal area; however, CD20-expressing cells were rare. D, E: CD38-expressing plasma cells were clustered around the blood vessel;
however, COX-2-expressing cells showed different distributions from inflammatory cells expressing CD38.
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3475Figure 7. Expression of cyclooxygenase-2 (COX-2) and CD68. Immunohistochemistry of adjacent sections of tissue using anti-COX-2
antibody and anti-CD68 antibody was performed in case 9 (A, B), case 2 (C, D), and case 10 (E-G). Arrows indicate the cells co-expressing
COX-2 and CD68. Not all CD68-expressing cells co-expressed COX-2; however, most COX-2-expressing cells co-expressed CD68. Panel
C includes the magnified image of COX 2-expressing cells that have a morphology suggesting macrophages. Panels E and F are stained with
fluorescent antibody targeting COX-2 (red) and CD68 (green). The merged image (panel G) shows that COX-2 and CD68 are expressed in
the same cells (arrow). The arrowhead indicates one macrophage that expressed CD68 but not COX-2.
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3476uniform  finding  of  stromal  COX-2-expressing  cells  and
increased  COX-2  expression  in  pterygia  having  more
prominent clinical appearance suggests that these cells are
closely  related  to  the  pathogenesis  or  maintenance  of
pterygium. These COX-2-expressing macrophages were also
found to infiltrate the epithelial layers.
Normal  conjunctiva  contains  a  local  surface  immune
system  called  conjunctiva-associated  lymphoid  tissue
(CALT) that contains T cells, B cells, and plasma cells as well
as local secretions of immunoglobulins (IgA, IgM, IgG, and
IgE) and complement [6,8,27,28]. This local immune system
is not homogeneously distributed in the whole conjunctiva.
Knop et al. [27] reported that CALT is more developed and
populated in tarsal, orbital, and fornix conjunctiva. Bulbar
conjunctiva  was  found  to  harbor  relatively  few  CALTs
compared to other parts of the conjunctiva. However, previous
studies  indicated  that  both  immune  cells  and
immunoglobulins are pathologically increased in pterygium
tissue, which indicates that the immunologic process might be
involved in its pathogenesis [6-8,29]. Although T cells are the
most frequently encountered type of inflammatory cell [6,7],
CD68-positive  macrophages  are  the  next  most  commonly
encountered in pterygium and they are distributed in both the
epithelial and stromal layers, suggesting that they are related
to disease pathogenesis. Additionally in the current study, we
found that some of these macrophages strongly expressed
COX-2 and VEGF in pterygium.
COX-2 is one of the key molecules in the induction of
angiogenesis in tumors [30]. Co-expression of COX-2 and
VEGF in several tumors has been previously reported [17,
31-33]. Exogenous addition of COX-2 protein can upregulate
VEGF production via the protein kinase C pathway in lung
cancer cells [20]. Prostaglandin E2, the product of COX-2
activity, is also angiogenic by direct influence on endothelial
cells or by inducing the release of angiogenic growth factors,
such as urokinase plasminogen activator receptor, fibroblast
growth factor receptor-1, and VEGF [34]. VEGF is a potent
stimulator of new vessels on the ocular surface. In the presence
of  VEGF,  endothelial  cells  proliferate,  migrate,  and
eventually form microvessels. Many studies have revealed the
importance of VEGF in the pathogenesis of pterygium [1,4,
26,35]. In our study, most VEGF expressing micro-vessels in
stromal layer was negative for COX-2 expression. This result
suggests that co-expression of COX-2 and VEGF in the same
cell is not prerequisite for VEGF expression. Both COX-2 and
VEGF can be therapeutic target in the treatment of pterygium.
Anti-angiogenesis therapy using anti-VEGF antibodies has
recently  been  reported  to  be  effective  in  both  controlling
primary pterygium and preventing recurrence after pterygium
excision [26,36-39]. And there was a report that selective
COX-2 inhibitor (Nimesulide) inhibited the proliferation of
pterygium fibroblast in dose dependent manner [40].
The finding that two important inflammatory molecules,
COX-2  and  VEGF,  are  highly  expressed  in  macrophages
infiltrating human pterygium suggests the critical role of these
Figure 8. Co-expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF). Immunohistochemistry of adjacent
sections of tissue using anti-COX-2 antibody (A) and anti-VEGF-A antibody (B) was performed in case 2. The arrows indicate cells co-
expressing  COX-2  and  VEGF-A.  VEGF-A-expressing  vascular  endothelial  cells  in  this  slide  were  negative  for  COX-2  expression.
(arrowheads).
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3477macrophages  in  pathogenesis.  Macrophage  expression  of
COX-2  was  previously  reported  in  several  inflammatory
disease and tumors [41-45]. In addition, recent studies have
demonstrated  that  VEGF  expression  in  macrophages  is
important in fibrosis and angiogenesis on the ocular surface
[46,47]. Therefore, macrophages expressing both COX-2 and
VEGF  may  have  the  potential  to  promote  angiogenesis,
collagen  deposition,  and  possibly  pterygium  growth.
Additionally, COX-2 and VEGF expression in macrophages
suggest a role for these cells as a bridge between the immune
process  and  the  tumor-like  characteristics  of  pterygium
because  both  COX-2  and  VEGF  are  important  in  skin
carcinogenesis induced by UV-light damage [48,49].
There is a limitation of this study. A small sample size
(n=17) of this study failed to provide significant evidence of
correlation between vascular endothelial COX-2 expression
and  clinical  severity.  Future  investigations  using  other
modalities such as cell models may provide stronger evidence.
In summary, the present study reveals a population of
macrophages expressing both COX-2 and VEGF in human
pterygium.  Despite  advances  in  the  treatment  and
management,  the  exact  pathogenesis  of  pterygium  is  still
unknown.  Considering  the  immunologic  and  tumor-like
characteristics  of  the  disease,  further  studies  about
macrophages expressing both COX-2 and VEGF may provide
a  more  comprehensive  understanding  about  human
pterygium.
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were observed. The inserted image is the magnification of the arrow-indicated area. E, F: Neither CD20-expressing cells nor CD38-expressing
cells were found.
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